Meta-analysis of these eight CVOTs with 60 080 patients included showed that GLP-1 receptor agonists reduce MACE and have a positive impact on chronic kidney disease in patients with T2D (30). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.